BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 31404982)

  • 1. The Inhibitory Effect of (-)-Epigallocatechin-3-Gallate on Breast Cancer Progression via Reducing
    Sheng J; Shi W; Guo H; Long W; Wang Y; Qi J; Liu J; Xu Y
    Molecules; 2019 Aug; 24(16):. PubMed ID: 31404982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines.
    Fang MZ; Wang Y; Ai N; Hou Z; Sun Y; Lu H; Welsh W; Yang CS
    Cancer Res; 2003 Nov; 63(22):7563-70. PubMed ID: 14633667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. (-)-Epigallocatechin-3-gallate reverses the expression of various tumor-suppressor genes by inhibiting DNA methyltransferases and histone deacetylases in human cervical cancer cells.
    Khan MA; Hussain A; Sundaram MK; Alalami U; Gunasekera D; Ramesh L; Hamza A; Quraishi U
    Oncol Rep; 2015 Apr; 33(4):1976-84. PubMed ID: 25682960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Green tea (-)-epigallocatechin-3-gallate down-regulates VASP expression and inhibits breast cancer cell migration and invasion by attenuating Rac1 activity.
    Zhang Y; Han G; Fan B; Zhou Y; Zhou X; Wei L; Zhang J
    Eur J Pharmacol; 2009 Mar; 606(1-3):172-9. PubMed ID: 19171136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. (-)-Epigallocatechin-3-gallate reactivates silenced tumor suppressor genes, Cip1/p21 and p16INK4a, by reducing DNA methylation and increasing histones acetylation in human skin cancer cells.
    Nandakumar V; Vaid M; Katiyar SK
    Carcinogenesis; 2011 Apr; 32(4):537-44. PubMed ID: 21209038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic and genetic mechanisms contribute to telomerase inhibition by EGCG.
    Berletch JB; Liu C; Love WK; Andrews LG; Katiyar SK; Tollefsbol TO
    J Cell Biochem; 2008 Feb; 103(2):509-19. PubMed ID: 17570133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Domain and functional analysis of a novel breast tumor suppressor protein, SCUBE2.
    Lin YC; Chen CC; Cheng CJ; Yang RB
    J Biol Chem; 2011 Jul; 286(30):27039-47. PubMed ID: 21652720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigallocatechin-3 gallate induces growth inhibition and apoptosis in human breast cancer cells through survivin suppression.
    Tang Y; Zhao DY; Elliott S; Zhao W; Curiel TJ; Beckman BS; Burow ME
    Int J Oncol; 2007 Oct; 31(4):705-11. PubMed ID: 17786300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potentiation of growth inhibition and epigenetic modulation by combination of green tea polyphenol and 5-aza-2'-deoxycytidine in human breast cancer cells.
    Tyagi T; Treas JN; Mahalingaiah PK; Singh KP
    Breast Cancer Res Treat; 2015 Feb; 149(3):655-68. PubMed ID: 25663548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor suppressor SCUBE2 inhibits breast-cancer cell migration and invasion through the reversal of epithelial-mesenchymal transition.
    Lin YC; Lee YC; Li LH; Cheng CJ; Yang RB
    J Cell Sci; 2014 Jan; 127(Pt 1):85-100. PubMed ID: 24213532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EGFR inhibition by (-)-epigallocatechin-3-gallate and IIF treatments reduces breast cancer cell invasion.
    Farabegoli F; Govoni M; Spisni E; Papi A
    Biosci Rep; 2017 Jun; 37(3):. PubMed ID: 28465354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EGCG down-regulates telomerase in human breast carcinoma MCF-7 cells, leading to suppression of cell viability and induction of apoptosis.
    Mittal A; Pate MS; Wylie RC; Tollefsbol TO; Katiyar SK
    Int J Oncol; 2004 Mar; 24(3):703-10. PubMed ID: 14767556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. (-)-Epigallocatechin-3-gallate down-regulates EGFR, MMP-2, MMP-9 and EMMPRIN and inhibits the invasion of MCF-7 tamoxifen-resistant cells.
    Farabegoli F; Papi A; Orlandi M
    Biosci Rep; 2011 Apr; 31(2):99-108. PubMed ID: 20446926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The green tea polyphenol EGCG alleviates maternal diabetes-induced neural tube defects by inhibiting DNA hypermethylation.
    Zhong J; Xu C; Reece EA; Yang P
    Am J Obstet Gynecol; 2016 Sep; 215(3):368.e1-368.e10. PubMed ID: 26979632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic induction of tissue inhibitor of matrix metalloproteinase-3 by green tea polyphenols in breast cancer cells.
    Deb G; Thakur VS; Limaye AM; Gupta S
    Mol Carcinog; 2015 Jun; 54(6):485-99. PubMed ID: 24481780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The anti-cancer effects of (-)-epigallocatechin-3-gallate on the signaling pathways associated with membrane receptors in MCF-7 cells.
    Hsu YC; Liou YM
    J Cell Physiol; 2011 Oct; 226(10):2721-30. PubMed ID: 21792929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigallocatechin-3-gallate up-regulates tumor suppressor gene expression via a reactive oxygen species-dependent down-regulation of UHRF1.
    Achour M; Mousli M; Alhosin M; Ibrahim A; Peluso J; Muller CD; Schini-Kerth VB; Hamiche A; Dhe-Paganon S; Bronner C
    Biochem Biophys Res Commun; 2013 Jan; 430(1):208-12. PubMed ID: 23201574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction in promotor methylation utilizing EGCG (epigallocatechin-3-gallate) restores RXRα expression in human colon cancer cells.
    Morris J; Moseley VR; Cabang AB; Coleman K; Wei W; Garrett-Mayer E; Wargovich MJ
    Oncotarget; 2016 Jun; 7(23):35313-26. PubMed ID: 27167203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The green tea catechins, (-)-Epigallocatechin-3-gallate (EGCG) and (-)-Epicatechin-3-gallate (ECG), inhibit HGF/Met signaling in immortalized and tumorigenic breast epithelial cells.
    Bigelow RL; Cardelli JA
    Oncogene; 2006 Mar; 25(13):1922-30. PubMed ID: 16449979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigallocatechin gallate (EGCG) suppresses growth and tumorigenicity in breast cancer cells by downregulation of miR-25.
    Zan L; Chen Q; Zhang L; Li X
    Bioengineered; 2019 Dec; 10(1):374-382. PubMed ID: 31431131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.